That's the initial consideration. After later reports from the parent company showed that sales for FY17 would be $US700 to $US750, the purchase agreement let Hikma renegotiate the cash upfront down by $US550m... from I think the initial agreement of $1.1B.
So final price for Roxanne was $2.1B, at operating margin of 35% like you quoted up there, that's EBIT of .35*700 = $US245m, or 8.6 P/EBIT.
Maybe paid practically $AUD1B [when you include the transaction, working capital, technical transfer] for a portfolio with FY17 sales of $US237m. EBITDA margin at 50% [they reckon] put earnings at $US118.5.
At current exchange rate, that's price of $US780m to $US118.5 or 6.58.
So it's cheaper on that PE measure. Here's the BUT...
Hikma's purchase only dilute its ownership b 16.7% compare to Mayne's issuing the equivalent of some 80% of existing shares.
Hikma immediately become the top 6 generic company vs Mayne's top 25.
Pipeline potentials of some US41b vs $US7b.
Get the labs, the R&D team and continued shared interests from the seller.
- Forums
- ASX - By Stock
- Fundamentals Are Strong
That's the initial consideration. After later reports from the...
-
-
- There are more pages in this discussion • 834 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.72 |
Change
0.040(0.85%) |
Mkt cap ! $401.5M |
Open | High | Low | Value | Volume |
$4.68 | $4.77 | $4.68 | $560.3K | 118.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 107 | $4.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.75 | 1500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 107 | 4.720 |
1 | 108 | 4.710 |
3 | 2594 | 4.700 |
2 | 594 | 4.690 |
2 | 594 | 4.680 |
Price($) | Vol. | No. |
---|---|---|
4.750 | 1500 | 1 |
4.760 | 648 | 1 |
4.770 | 648 | 1 |
4.780 | 756 | 2 |
4.790 | 2511 | 2 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online